Waters Corporation · NYSE:WAT
Waters — Q3 2026 Earnings Presentation
30 slides from Waters's earnings presentation, Nov 3, 2026
Slide 1: Q3 2026 Earnings Call Presentation
Q3 2026 Earnings Call Presentation November 3, 2026 0
Slide 2: Introduction
Introduction Caspar Tudor Head of Investor Relations 1
Slide 3: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements regarding future results and events, including financial and operational guidance and projected estimates. For this purpose, any statements that are not statements of historical fact may be
Slide 4: Agenda
Agenda 01 CEO Remarks 02 Financial Results & Outlook 03 Q&A 3
Slide 5: CEO Remarks
CEO Remarks Dr. Udit Batra President & Chief Executive Officer 4
Slide 6: Key Messages
Key Messages $43M Guide Double-Digit Raise as Strong Setup Organic CC Momentum Ahead Growth Accelerates Note: CC = Constant Currency. Organic growth presented in constant currency is a non-GAAP financial measure. A reconciliation of this non-GAAP financial measure to the most directly comparable GAA
Slide 7: Q3 2026 Results – Overview
Q3 2026 Results – Overview Total Revenue Organic Revenue Biosciences & Diagnostic Solutions Revenue $1.767B $871M $896M Adj. EPS = As Reported: + As Reported: $4.10 +9% +1% Growth Constant Currency: Consistent with +21% +10% Guided Seasonality Note: Growth measures presented in constant currency and
Slide 8: Q3 2026 Results – By Division
Q3 2026 Results – By Division Analytical Sciences Biosciences Advanced Diagnostics Materials Sciences Q3 2026 Revenue Q3 2026 Revenue Q3 2026 Revenue Q3 2026 Revenue $703M $396M $575M $93M = +8% +2% +2% +7% + + As Reported As Reported As Reported As Reported $500M $75M DS CBU +9% 0% As Reported +17%
Slide 9: Key Growth Acceleration in 3Q Results
Key Growth Acceleration in 3Q Results Flow Reagent Chemistry LC-MS Consumables Consumables Instruments +HSD +12% +10% IN BIOSCIENCES IN ANALYTICAL IN ANALYTICAL DIVISION SCIENCES DIVISION SCIENCES DIVISION (As Reported Growth) (Constant Currency Growth) (Constant Currency Growth) +400bps +200bps +20
Slide 10: Rapid Execution Initiatives to Accelerate BS/Dx Growth
Execution Uplift Already Driving MSD BS/Dx Growth Rapid Execution Pricing Action: Central pricing team & deal desks established Result: Net price realization scaled to 120bps in 3Q Initiatives to 150bps+ BS/Dx price realization expected ahead Accelerate Reagent Rental Compliance Action: Dedicated te
Slide 11: Full Tranche of Revenue Synergies Now Entering
Full Tranche of Revenue Synergies Now Entering Cross Instrument Service Digital Selling Replacement Attachment Commerce Early wins in DMPK Both BACTEC FXI & Now Driving Service Now Leveraging New Cross-Selling FACSDiscover A7 Now Plan Attachment Digital Channels Launched Increase On Track to Deliver
Slide 12: Legacy Waters Remains a Durable HSD Grower
Legacy Waters Remains a Durable HSD Grower Consistently Still only in Mid-Innings Plus New Growth Delivering Industry- of Instrument Vectors Building Leading Results Replacement Cycle 8% + Reshoring Average Organic + Semiconductor & CC Growth over Idiosyncratic growth drivers still scaling + Data Ce
Slide 13: AI has become a Key Topic with our Customers
AI has become a Key Topic with our Customers Waters = Key Leader in AI Transformation of the Lab Enabled by a long-standing strategy that leverages a unique market position: 1 2 3 Advancing lab-in-the-loop Leveraging decades of Enabling AI, ML & automation research, while enabling compliant propriet
Slide 14: AI is Reshaping Pharma Research, Development & QC
AI is Reshaping Pharma Research, Development & QC AI-Driven Volume Increase for Waters AI-Enabled Value Increase for Waters More LC-MS AI generates Each becomes a Launching new Premium SaaS More revenue runs & column more hypotheses physical sample Empower AI features subscription tier per lab consu
Slide 15: MOBILion Acquisition: Enabling End-to-End Proteomics
MOBILion Acquisition: Enabling End-to-End Proteomics Pairing unique separation technology w/ industry-leading mass spec capabilities Research Development LC-MS Diagnostics Enables Waters to Enter Leveraging Waters Ability Future Menu Expansion Attractive Proteomics to Take Proteomics for Blood-Based
Slide 16: New Sources of Growth Strengthen 2027 Setup
New Sources of Growth Strengthen 2027 Setup Legacy WAT 2027 Starting 2027 Potential 2027 Potential: Drivers Legacy BD Assumption + Execution Initiatives Organic 7% + Revenue Synergies Revenue MSD+ + Reshoring 5% + AI-Driven Demand Growth MSD 9% + Semiconductor Testing HSD 2H26 Guidance Adj. + Volume
Slide 17: Financial Results & Outlook
Financial Results & Outlook Amol Chaubal Senior Vice President & Chief Financial Officer 16
Slide 18: Q3 2026 Financial Results
Q3 2026 Financial Results Total Revenue $1.767B Asia $495M Americas = $749M Europe $523M Organic Revenue $871M + Biosciences & Diagnostic Solutions Revenue $896M Adj. Operating Margin Adj. EPS Adj. EPS Growth 30.1% $4.10 +21% Note: Adj. Operating Margin, Adj. EPS and Adj. EPS growth are non-GAAP fin
Slide 19: Analytical Sciences Division (ASD)
Analytical Sciences Division (ASD) Category-defining Brands Analytical Sciences Performance Commentary Chemistry Service Q3 2026 Revenue in CC $157M $265M $703M +12% +8% DD Pharma growth, driven by instrument replacement, GLP-1s, Y/Y Growth India generics, and large molecule in CC applications. +8
Slide 20: Biosciences Division (WBD)
Biosciences Division (WBD) Category-defining Brands FACSDiscover FACSLyric Horizon Biosciences Performance Commentary Flow Clinical Q3 2026 Revenue $182M $396M +4% Reagents grew high single- digits, with high-single-digit growth across both research and clinical applications. Solid demand for ne
Slide 21: Advanced Diagnostics Division (ADx)
Advanced Diagnostics Division (ADx) Category-defining Brands BACTEC Phoenix Kiestra Synapsys BD MAX Advanced Diagnostics Performance Commentary MSDx MDx & PoC Q3 2026 Revenue $75M $154M $575M +17% (6%) In Microbiology, ex-China growth was 6%, led by high single-digit = growth in the Americas. In
Slide 22: Materials Sciences Division (MSD)
Materials Sciences Division (MSD) Category-defining Brands Materials Sciences Performance Commentary Service Q3 2026 Revenue $29M in CC $93M +9% Growth led by electronics testing for semiconductor and data center Y/Y Growth applications in CC Continued strength in thermal +7% analysis for aerosp
Slide 23: FY & Q4 2026 Guidance
FY & Q4 2026 Guidance FY 2026 Q4 2026 Organic CC Revenue Growth +9.1% to +9.7% Organic CC Revenue Growth +7.0% to +9.0% FX (0.7%) FX (1.5%) Organic Reported Revenue $3.429B to $3.447B Organic Reported Revenue $984M to $1.002B Acquired Business Contribution +$3.050B Acquired Business Contribution +$8
Slide 24: Q&A Session
Accelerating Q&A Session the Benefits of Pioneering Q3 2026 Earnings Call Science 23
Slide 25: Appendix: GAAP to Non-GAAP Reconciliations
Appendix GAAP to Non-GAAP Reconciliations 24
Slide 26: Q3 2026 – Reconciliation of Revenue Growth
Q3 2026 – Reconciliation of Revenue Growth (in millions USD) 2026 2025 Total Reported Revenue (GAAP) 1,767 800 Acquired Business Contribution 896 - Reconciliation of Total Organic Reported Revenue 871 800 Organic Revenue Growth Organic Reported Revenue Growth 9% Currency Translation Impact (1%) Orga
Slide 27: Q3 2026 – Reconciliation of Organic Revenue Growth
Q3 2026 – Reconciliation of Organic Revenue Growth % Growth % Growth Constant (in millions USD) 2026 2025 Impact of Currency Reported Currency Instruments 282 257 9% (1%) 10% Analytical Sciences Service 265 249 6% (2%) 8% Division (ASD) Chemistry 157 143 10% (2%) 12% Analytical Sciences Division Rev
Slide 28: Q3 2026 – Reconciliation Prior Year Comparable Revenue Growth
Q3 2026 – Reconciliation Prior Year Comparable Revenue Growth % Growth (in millions USD) 2026 2025 Reported Flow Research 214 212 1% Reconciliation of Biosciences Prior Year Flow Clinical 182 174 4% Comparable Revenue Total Biosciences – Q3 396 387 2% % Growth (in millions USD) 2026 2025 Reported Di
Slide 29: Q3 2026 – Reconciliation of Adjusted Operating Income
Q3 2026 – Reconciliation of Adjusted Operating Income Q3 2026 Q3 2026 Q3 2026 Q3 2026 (in millions USD) Operating Operating Gross Margin Gross Margin % Income Income % GAAP 887 50.2% 128 7.2% Adjustments: Purchased intangibles and acquisition step-up amortization (a) 80 4.5% 323 18.3% Restructuring
Slide 30: Reconciliation of Adjusted EPS & 2026 Guidance
Reconciliation of Adjusted EPS & 2026 Guidance Reconciliation of Adjusted Earnings Per Share FY 2026 and Q4 2026 Revenue & EPS Guidance Q3 2026 Q3 2025 Projected Revenue FY 2026 Q4 2026 GAAP $0.82 $2.50 Reported revenue $6,479 - $6,497 $1,801 - $1,819 Adjustments: Acquired business contribution $3,0